This publication is a user-friendly guide, taking the reader, step by step, through the trendspotter methodology developed by the EMCDDA to explore emerging drug trends, new patterns of use, developing drug markets and technologies. The trendspotter method involves the rapid collection and triangulation of data from a variety of sources, incorporating multiple social research methods, and drawing on rapid assessment and response methods.
Using trendspotter methodology, this report explores signs of increasing availability and consumption of cocaine in Europe, in an effort to increase our understanding of recent changes in the cocaine market. The study investigates the consequences of these developments on acute health harms linked to cocaine and crack use and reviews the current public health responses to problems related to these drugs.
The latest changes in Europe’s cocaine market are explored in a new report published today by the EU drugs agency (EMCDDA). The report follows an analysis in the European Drug Report 2018, which highlighted an increase in the availability of high-purity cocaine in Europe, shifting trafficking routes and rising numbers of first-time admissions to specialised treatment.
This month, the EMCDDA approaches the end of its presidency of the EU Agencies’ Network on Scientific Advice (EU-ANSA) and looks back on a productive year (1).
This report provides a summary of the key findings from the assessment of progress of the EU Member States, Norway and Turkey towards the implementation of the revised drug supply indicators, as developed by the EMCDDA in line with the Council conclusions of November 2013. The report gives also an overview of the purpose and aims of supply data collected by the EMCDDA.
Europe’s ability to rapidly respond to public health and social threats caused by new psychoactive substances (NPS/‘new drugs’) has been significantly strengthened thanks to new legislation applying from 23 November (1). The legislation strengthens the EU Early Warning System (EU EWS) and risk assessment procedures on NPS and shortens control processes.
What is the evidence base for the medical use of cannabis and cannabinoids? What is the difference between cannabis preparations and medicinal products and why is this important? How is this issue regulated in the EU? These and other questions are explored in this report which responds to growing interest in this topic as more European countries develop policies and practice in this area.
What is the evidence base for the medical use of cannabis and cannabinoids? What is the difference between cannabis preparations and medicinal products and why is this important? How is this issue regulated in the EU? These and other questions are explored in a new report published today by the EU drugs agency (EMCDDA): Medical use of cannabis and cannabinoids: questions and answers for policymaking.
Over 50 representatives of the Reitox national focal points (NFPs) and decision-makers from more than 20 countries will gather in Prague this week for a Reitox academy on the theme of prevention (1). The two-day course will centre on the European adaptation of the Universal Prevention Curriculum (UPC), taken forward by the European Commission-funded Universal Prevention Curriculum in Europe project (UPC-ADAPT)(2)(3).
This page describes the work and main outputs of the EU Early Warning System on new psychoactive substances. It includes a description of how the system work, an historical timeline of legislation and substances investigated, and NPS drug profiles.
Europe’s ability to rapidly respond to public health and social threats caused by new psychoactive substances (NPS/‘new drugs’) will be significantly strengthened, thanks to new legislation applying from today (1).
The legislation — applicable across Europe from 23 November 2018 — strengthens the EU Early Warning System (EU EWS) and risk assessment procedures on NPS and shortens control processes. The legislation comes in response to the recent growth in the availability of NPS and follows proposals from the European Commission (EC).
This report details the results of a two-day workshop on the EMCDDA’s trendspotter methodology held in Lisbon in November 2017. The workshop involved representatives from national drug observatories based in countries from the Community of Latin American and Caribbean States (CELAC), along with experts from European countries and regional and international organisations active in the drugs field.
This news item was published in the EMCDDA’s Cannabis drug policy news on 16.11.2018
This report explores how data on drug use are captured through surveys of targeted populations in recreational settings. The benefits and challenges of monitoring drug use in recreational settings are identified, as are emergent data sources and methodological innovations. The report draws on cutting-edge debates within social research, sociology and critical drug studies to encourage dialogue between researchers and with monitoring agencies.
This document is an update of the International Cooperation Strategy adopted in 2007. It sets priorities in the area of the international cooperation aligned with the Centre’s Strategy 2025.
How to build a better picture of substance use in recreational settings is explored today in a new EMCDDA report: Monitoring drug use in recreational settings across Europe: conceptual challenges and methodological innovations.
The report examines how drug-use data are currently collected in recreational settings, and identifies the benefits and challenges of monitoring in these milieux.
Winners of the 2018 EMCDDA scientific award were announced by the EU drugs agency today in the margins of its 49th Scientific Committee meeting in Lisbon (1). The acclaimed writers will be invited to Lisbon next autumn to present their articles during the conference Lisbon Addictions 2019, convening from 23–25 October in the Portuguese capital (2).
Representatives of candidate, potential candidate and neighbouring countries of the EU and countries of Central Asia are joining members of the EMCDDA’s Reitox network (1) in Lisbon from 12–16 November for the agency’s seventh Reitox week. The purpose of this annual event is to broaden the scope of the regular Heads of national focal point (NFP) meetings, underline the usefulness of the EU drug monitoring model; add impetus to the agency’s technical cooperation with countries outside the EU and learn from each other’s experience.
The EMCDDA receives stable funding under Commission budget line B3-441 of the general budget of the European Union. Each year, a preliminary draft budget is presented by the Centre's Director to the Management Board, which may modify the draft before adopting it and submitting it to the European Commission. The Commission, in turn, makes its recommendations (which may again alter the draft) and presents the result to the European Council and Parliament.
What do we know about how research evidence is used in the ‘real world’ of prevention? How can we take advantage of technology to promote the use of evidence in policy and practice? What are some of the biggest implementation challenges in prevention and how do we address these? These are among the questions being addressed this week at the 9th annual conference of the European Society for Prevention Research (EUSPR) (24–26 October).
Leading international experts in the field of addiction science will meet in Lisbon from 23–25 October 2019 for the Third European conference on addictive behaviours and dependencies. The theme of the conference is ‘The future of addictions: new frontiers for policy, practice and science’. Registration and a call for abstracts open today.
Captagon is reported to be a commonly used stimulant in the Middle East. In addition, some recent media reports have linked this drug to perpetrators of terrorist acts in Europe or terrorist groups based in areas of conflict in the Middle East. This report aims to provide an overview of what is known about the captagon phenomenon, and how it may concern Europe, to assist those working in the illicit drugs field who may need to respond to the issue.
What is captagon? Where is it used and produced? Can it be linked to terrorist attacks in Europe? These are some of the questions explored in the latest edition in the EMCDDA Papers series launched today Captagon: understanding today’s illicit market. The report provides an overview of what is currently known about the captagon phenomenon in order to assist those working in the illicit drugs field who may need to respond to the issue.
EMCDDA Director Alexis Goosdeel is paying an official visit to Cyprus today, where he is meeting with health and security officials. This is in line with the EMCDDA Strategy 2025, which aims to contribute to a healthier and more secure Europe.
This news item was published in the EMCDDA’s Cannabis drug policy news on 09.10.2018
More than 9 000 lives were reported to be lost to drug overdoses in Europe (28 EU Member States, Turkey and Norway) in 2016, the latest reporting year, and this is an underestimate. Reducing drug-related deaths therefore remains a major challenge for public health policy. This analysis describes some of the factors that increase the risk of fatal and non-fatal overdoses and a number of interventions developed to prevent these events.
EMCDDA Director Alexis Goosdeel is participating this week in the EU-Western Balkans Ministerial Forum on Justice and Home Affairs, taking place from 4–5 October in Tirana.
EMCDDA Director Alexis Goosdeel is paying an official visit to Germany today at the invitation of the Federal Drug Commissioner Marlene Mortler. Discussions will centre on the further development of cooperation between Germany and the EMCDDA and the agency’s work priorities as outlined in Strategy 2025 and the Programming document 2018–20.
Today, the European Union has decided to subject two new synthetic opioids to control measures across the 28 Member States. The implementing decision of the Council of the EU (1), based on a proposal from the European Commission, was adopted in the final stage of the three-step legal procedure designed to respond to new psychoactive substances (NPS) that may pose public health and social threats (2)(3).